Eli Lilly and Company(LLY) - Stock detail

Eli Lilly and Company

US
LLY
Eli Lilly and Company(Listing date: 07/09/1970)

Eli Lilly and Company was incorporated in Indiana in 1901, with its predecessor being a pharmaceutical manufacturing enterprise founded by Colonel Eli Lilly in Indianapolis, Indiana in 1876. The company develops, manufactures and markets important pharmaceutical products. Its mission is to combine "Caring" and "Discovery" to create better lives for people around the world.

AI Rating

Rating methodology
Latest close (chg%)1003.57-0.41%
Buy price
1003.57
Target price1248.00
Sell price950.00
P/E TTM47.85
P/E91.43
Confidence70%
Risk score60/100
AI Summary
Exceptional fundamental strength with 94.9% net income growth and 44.7% revenue growth justifies premium valuation. Oversold technical conditions (RSI: 38, Williams %R: -86.49) present entry opportunity in dominant GLP-1 market player. Historical data shows similar oversold conditions led to 12.97% gains. Disciplined stop-loss manages downside risk.

Alpha Score

0-10
  • Trend（Score 4/10）

    Eli Lilly and Company is in a corrective phase with oversold technical characteristics suggesting potential for rebound but continued short-term weakness.

  • Valuation（Score 7/10）

    Current valuation appears fairly valued to slightly undervalued relative to growth prospects, with elevated PE ratios (TTM PE 47.85) justified by strong growth trajectory and premium PB ratio (41.51) common for high-growth pharma firms.

  • Financial strength（Score 8/10）
    Strong financial condition with revenue of $65.18B showing robust growth (+44.70% YoY) and net income of $20.64B (+94.90% YoY). High profitability suggests solid cash flow generation, though specific liquidity ratios and debt metrics are not provided.
  • Profitability（Score 10/10）
    Exceptional profitability with gross margin of 83.04%, net margin expanded to 31.67% from 23.51% in 2024, driven by revenue growth and operational efficiencies. ROE surged to 290.87% and ROA reached 52.44% with accelerating EPS growth.
  • Sentiment（Score 8/10）
    Eli Lilly demonstrates strong pipeline growth with positive regulatory developments and competitive positioning in GLP-1 market, though valuation concerns warrant careful entry points.
Latest price
$1003.57-0.41%
Market cap947.89B
P/E TTM47.85
P/E91.43
Volume1.93M
Turnover1.95B